- Societal CDMO (NASDAQ:SCTL) has announced an amendment to its license and supply deal with Lannett Company for the marketing of Verapamil PM and Verelan SR products.
- The amendment awards Societal (SCTL) potential new GMP manufacturing agreements targeting injectable products for multiple additional Lannett development projects.
- The CDMO will also receive improved overall economics, including a 10% growth in the profit share component of revenue from Verapamil PM product sales, as well as immediate and scheduled increases in manufacturing prices.
Recommended For You
More Trending News
See More »